Recro Pharma (NASDAQ: REPH) is one of 298 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Recro Pharma to related businesses based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, dividends and valuation.
This table compares Recro Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Recro Pharma Competitors||-5,409.43%||-437.09%||-41.74%|
Earnings & Valuation
This table compares Recro Pharma and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Recro Pharma||$69.34 million||-$30.20 million||-3.99|
|Recro Pharma Competitors||$290.00 million||$35.57 million||-5.04|
Recro Pharma’s rivals have higher revenue and earnings than Recro Pharma. Recro Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
65.1% of Recro Pharma shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 21.6% of Recro Pharma shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Recro Pharma has a beta of -0.56, suggesting that its stock price is 156% less volatile than the S&P 500. Comparatively, Recro Pharma’s rivals have a beta of 6.53, suggesting that their average stock price is 553% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Recro Pharma and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Recro Pharma Competitors||769||3078||11289||227||2.71|
Recro Pharma currently has a consensus target price of $13.50, indicating a potential upside of 53.06%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 25.62%. Given Recro Pharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Recro Pharma is more favorable than its rivals.
Recro Pharma beats its rivals on 8 of the 12 factors compared.
About Recro Pharma
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
What are top analysts saying about Recro Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Recro Pharma Inc. and related companies.